Vedolizumab, an integrin receptor antagonist, has been approved as a treatment for moderate to severe inflammatory bowel disease in adults who have not had an adequate response to one or more...

Field of Interest: Gastroentero...

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness